Safety of Intravenous Infusion of BPC-157 in Humans: A Pilot Study

Plain-language summary

This IRB-approved pilot study assessed the safety of intravenous BPC-157 administration in two healthy adult participants, monitoring blood work and vital signs before and after each infusion. Intravenous infusion of up to 20 mg of BPC-157 showed no adverse effects and was well-tolerated in both subjects. The authors concluded that the results support the safety of intravenous BPC-157 in humans, while noting that larger future studies are needed to confirm these preliminary findings.